The US Food and Drug Administration's approval of anti-amyloid therapies for the treatment of Alzheimer's dementia has resulted in a proliferation of publications reporting and conveying rapidly changing information. Unfortunately for the clinician, this information is surfacing in a variety of places and formats without a unifying consensus or clear guidance.